Literature DB >> 17909911

Improved long-term outcome of surgery for advanced colorectal liver metastases: reasons and implications for management on the basis of a severity score.

Axel Andres1, Pietro E Majno, Philippe Morel, Laura Rubbia-Brandt, Emiliano Giostra, Pascal Gervaz, Sylvain Terraz, Abdelkarim S Allal, Arnaud D Roth, Gilles Mentha.   

Abstract

BACKGROUND: The outcome of liver resection for colorectal liver metastases (CRLM) appears to be improving despite the fact that surgery is offered to patients with more-severe disease. To quantify this assumption and to understand its causes we analyzed a series of patients on the basis of a standardized severity score and changes in management occurring over the years.
METHODS: Patients' characteristics, operative data, chemotherapies and follow-up were recorded. CRLM severity was quantified according to Fong's clinical risk score (CRS), modified to take into account the presence of bilateral liver metastases. Three periods were analyzed, in which different indications, surgical strategies and uses of chemotherapy were applied: 1984-1992, 1993-1998, and 1999-2005.
RESULTS: Between January 1984 and December 2005, 210 liver resections were performed in 180 patients (1984-1992, 43 patients; 1993-1998, 42 patients; 1999-2005, 95 patients). CRLM severity increased throughout the time periods, as did the use of neoadjuvant chemotherapies, repeat resections, and multistep procedures. While the disease-free survival did not improve over time, the 1-, 3- and 5-year overall survival rate increased from 85%, 30%, and 23% in the first period, to 88%, 60%, and 34% in the second period, and to 94%, 69%, and 46% in the third period.
CONCLUSIONS: Analysis according to the CRS showed that despite the fact that patients had more severe disease, the overall survival improved over the years, mainly thanks to more aggressive treatment of recurrent disease. Management of advanced CRLM should, from the start, take into account the likelihood of secondary procedures.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17909911     DOI: 10.1245/s10434-007-9607-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  18 in total

1.  Survival after lung metastasectomy in colorectal cancer patients with previously resected liver metastases.

Authors:  Michel Gonzalez; John Henri Robert; Nermin Halkic; Gilles Mentha; Arnaud Roth; Thomas Perneger; Hans Beat Ris; Pascal Gervaz
Journal:  World J Surg       Date:  2012-02       Impact factor: 3.352

Review 2.  Multidisciplinary management in rectal cancer.

Authors:  Asunción Hervás Morón; María Luisa García de Paredes; Eduardo Lobo Martínez
Journal:  Clin Transl Oncol       Date:  2010-12       Impact factor: 3.405

Review 3.  Viral vector-based therapeutic cancer vaccines.

Authors:  Cecilia Larocca; Jeffrey Schlom
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

Review 4.  Clinical evaluation of TRICOM vector therapeutic cancer vaccines.

Authors:  Ravi A Madan; Marijo Bilusic; Christopher Heery; Jeffrey Schlom; James L Gulley
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

Review 5.  Treatment Options in Colorectal Liver Metastases: Hepatic Arterial Infusion.

Authors:  Alice Zervoudakis; Taryn Boucher; Nancy E Kemeny
Journal:  Visc Med       Date:  2017-02-03

6.  A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer.

Authors:  Michael A Morse; Donna Niedzwiecki; John L Marshall; Christopher Garrett; David Z Chang; Mebea Aklilu; Todd S Crocenzi; David J Cole; Sophie Dessureault; Amy C Hobeika; Takuya Osada; Mark Onaitis; Bryan M Clary; David Hsu; Gayathri R Devi; Anuradha Bulusu; Robert P Annechiarico; Vijaya Chadaram; Timothy M Clay; H Kim Lyerly
Journal:  Ann Surg       Date:  2013-12       Impact factor: 12.969

7.  Pathological response grade of colorectal liver metastases treated with neoadjuvant chemotherapy.

Authors:  Gabriel Chan; Mazen Hassanain; Prosanto Chaudhury; Dionisios Vrochides; Amy Neville; Matthew Cesari; Petr Kavan; Victoria Marcus; Peter Metrakos
Journal:  HPB (Oxford)       Date:  2010-05       Impact factor: 3.647

Review 8.  Therapeutic cancer vaccines: current status and moving forward.

Authors:  Jeffrey Schlom
Journal:  J Natl Cancer Inst       Date:  2012-03-06       Impact factor: 13.506

9.  Predicting survival after pulmonary metastasectomy for colorectal cancer: previous liver metastases matter.

Authors:  Ulrich Landes; John Robert; Thomas Perneger; Gilles Mentha; Vincent Ott; Philippe Morel; Pascal Gervaz
Journal:  BMC Surg       Date:  2010-06-03       Impact factor: 2.102

10.  A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases.

Authors:  Oliver F Bathe; Scott Ernst; Francis R Sutherland; Elijah Dixon; Charles Butts; David Bigam; David Holland; Geoffrey A Porter; Jennifer Koppel; Scot Dowden
Journal:  BMC Cancer       Date:  2009-05-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.